Biomimetic Therapeutics logo

Biomimetic Therapeutics

BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments. BioMimetic received regulatory approval in 2009 and 2011 to market Augment in Canada, and in Australia for hindfoot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications.

Free account • No credit card • 5 profiles/day

Biotechnology Research 15 Employees Found Franklin, United States Founded 2000 33141 Similar Companies
15 Employees Found
96% Email Coverage
$1.7M Est Revenue
1 Office HQ
33141 Similar Companies

Frequently asked questions about Biomimetic Therapeutics

What is Biomimetic Therapeutics email format?

The widely used Biomimetic Therapeutics email format is {first_initial}{last} (e.g. jsmith@biomimetics.com) with 83.33% adoption across the company.

What is Biomimetic Therapeutics customer service number?

To contact Biomimetic Therapeutics customer service number in your country click here to find.